Its main investigated use is chronic weight management, either alone or combined with semaglutide as CagriSema
The patent dispute is unfolding as India becomes one of the most competitive emerging markets for GLP-1 agonists
Start with a half-dose for the first week
The most common side effects include: Nausea: The most frequently reported side effect, affecting roughly 20-30% of patients
In adults with obesity, daily subcutaneous administration of 3.0 mg liraglutide in combination with lifestyle therapy results in a reduction in body weight of approximately 8%
While, the major focus is on the impact of GLP-1 compositions on appetite control, eating patterns, and its glycaemic responses from the premier universities and pharmaceutical companies, there were very few F&B ingredient companies like Roquette Frres and DSM, who were trying to validate the impact of their existing products such as pea proteins and beta-glucans in conjunction with GLP-1 compositions